{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:32:17Z","timestamp":1790771537978,"version":"4.1.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Simple summary<\/jats:title>\n                    <jats:p>\n                      We investigated the role of Ki67, a ubiquitous marker in cancer, within the context of ductal carcinoma\n                      <jats:italic>in situ<\/jats:italic>\n                      (DCIS), a precursor of invasive breast cancer. Through rigorous analysis of histopathological and immunopathological samples from a substantial cohort, this study revealed robust correlations between heightened Ki67 expression, diminished progesterone (PR) levels, and HER2 overexpression, indicative of aggressive DCIS phenotypes. These findings offer novel insights into the surrogate immunomolecular subtyping landscape of DCIS, potentially refining risk stratification and therapeutic approaches. This elucidation underscores the translational significance of Ki67 as a prognostic and predictive biomarker in DCIS, with implications for personalized treatment paradigms and patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The Ki67 proliferation index is widely used in various tumors, including invasive breast carcinoma (IBC). However, its prognostic utility is often constrained by technical complexity. Its diagnostic and clinical significance in ductal carcinoma\n                      <jats:italic>in situ<\/jats:italic>\n                      (DCIS) remains uncertain. We studied Ki67 immunohistochemistry interobserver diagnostic agreement at different cutoff values in high-grade DCIS. Additionally, we investigated the associations between Ki67 expression, PR levels, and human epidermal growth factor receptor 2 (HER2) in high-grade DCIS among various subtypes (Luminal (Lum) A, LumB HER2\n                      <jats:sup>-<\/jats:sup>\n                      , LumB HER2\n                      <jats:sup>+<\/jats:sup>\n                      , HER2-enriched, and triple-negative)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using histopathological specimens from 484 patients diagnosed with DCIS between 1996 and 2018, we implemented the 2013 St. Gallen recommendations for surrogate immunomolecular subtyping of IBC. Subtypes were classified, and the Ki67 interobserver diagnostic agreement between Counting Pathologist 1 (CP1) and CP2 was calculated using Cohen\u2019s kappa coefficient at various cutoff values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Cohen\u2019s kappa coefficient for interobserver agreement between CP1 and CP2 was \u03ba = 0.586, indicating moderate agreement. Ki67 levels varied significantly among subtypes (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001), with a median Ki67% being higher in cases with invasive components (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0351). Low PR combined with high Ki67% was significantly associated with HER2 overexpression (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0107).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Interobserver agreement for the Ki67 count was moderate. Ki67 expression showed considerable variability in high-grade DCIS. Low PR levels combined with high Ki67 expression were linked to HER2 overexpression, showing possible clinical implications for identifying high-risk DCIS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1467664","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T01:43:08Z","timestamp":1738028588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["High Ki67 expression, HER2 overexpression, and low progesterone receptor levels in high-grade DCIS: significant associations with clinical practice implications"],"prefix":"10.3389","volume":"15","author":[{"given":"Hossein","family":"Schandiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorant","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig N.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torill","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"B1","volume-title":"Key Statistics for Breast Cancer in the United States","year":"2024"},{"key":"B2","article-title":"Breast cancer Incidence and Mortality. National Cancer Institute","volume-title":"Breast Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version","year":""},{"key":"B3","volume-title":"Health and Economic Benefits of Breast Cancer Interventions","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41392-024-01779-3","article-title":"Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.019","article-title":"International variation in management of screen-detected ductal carcinoma in situ of the breast","volume":"50","author":"Ponti","year":"2014","journal-title":"Eur J Cancer"},{"key":"B7","unstructured":"Breast Screen Norway: 25years of organized screening\n          \n          \n            \n              Elin W\u00f8lner Bj\u00f8rnson\n              \u00c5SH\n            \n            \n              Solveig\n              H\n            \n          \n          Oslo\n          Cancer Registry of Norway\n          \n          2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07016-9","article-title":"Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact","volume":"201","author":"Schandiz","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1347166","article-title":"Low progesterone receptor levels in high-grade DCIS correlate with HER2 upregulation and the presence of invasive components","volume":"14","author":"Schandiz","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer outcomes in DCIS patients without locoregional treatment","volume":"111","author":"Ryser","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.01.001","article-title":"Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study","volume":"61","author":"Maxwell","year":"2022","journal-title":"Breast"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS616","article-title":"Comparing an operation to monitoring, with or without endocrine therapy (COMET), for low-risk ductal carcinoma in situ (DCIS)","volume":"40","author":"Lynch","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000223","article-title":"Her2 and ki67 biomarkers predict recurrence of ductal carcinoma in situ","volume":"24","author":"Davis","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1038\/s41598-022-06555-3","article-title":"Assessment of Ki-67 proliferation index with deep learning in DCIS (ductal carcinoma in situ)","volume":"12","author":"Fulawka","year":"2022","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604112","article-title":"Immunohistochemical categorisation of ductal carcinoma in situ of the breast","volume":"98","author":"Meijnen","year":"2008","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"210120","DOI":"10.1098\/rsob.210120","article-title":"The intrinsically disorderly story of Ki-67","volume":"11","author":"Remnant","year":"2021","journal-title":"Open Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/bcr3639","article-title":"A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue","volume":"16","author":"Laurinavicius","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of ki67 in breast cancer: updated recommendations from the international ki67 in breast cancer working group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000328054","article-title":"St. Gallen 2011: summary of the consensus discussion","volume":"6","author":"Gnant","year":"2011","journal-title":"Breast Care (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000351193","article-title":"St. Gallen 2013: brief preliminary summary of the consensus discussion","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07118-4","article-title":"Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system","volume":"203","author":"Shim","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112151-20220428-00339","article-title":"The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer","volume":"51","author":"Pan","year":"2022","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B29","article-title":"No increased ki67 expression in ductal carcinoma in situ associated with invasive breast cancer1","volume":"10","author":"Hoque","year":"2001","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90982-6","article-title":"Prognostic classification of breast ductal carcinoma-in-situ","volume":"345","author":"Silverstein","year":"1995","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.12.007","article-title":"Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ","volume":"44","author":"Maxwell","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/bcr1397","article-title":"Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective","volume":"8","author":"Jones","year":"2006","journal-title":"Breast Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2012.32.228","article-title":"Ductal carcinoma in situ: challenges, opportunities, and uncharted waters","volume":"2012","author":"Hoffman","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr3679","article-title":"Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes","volume":"16","author":"Maisonneuve","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.03.012","article-title":"Identification of luminal subtypes of breast carcinoma using surrogate immunohistochemical markers and ascertaining their prognostic relevance","volume":"20","author":"Sali","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"B39","unstructured":"VENTANA HER2 Dual ISH DNA Probe Cocktail\n          \n          \n          2020"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of american pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.11613\/issn.1846-7482","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"B42","unstructured":"Scientific online calculator\n          \n          \n            \n              Software\n              G\n            \n          \n          \n          2023"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000864","article-title":"Ki67 immunohistochemistry quantification in breast carcinoma: A comparison of visual estimation, counting, and immunoRatio","volume":"29","author":"van den Berg","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037379","article-title":"How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists","volume":"7","author":"Varga","year":"2012","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030233","article-title":"Ki67 in breast cancer assay: an ad hoc testing recommendation from the canadian association of pathologists task force","volume":"30","author":"Faragalla","year":"2023","journal-title":"Curr Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"PD2","DOI":"10.1158\/1538-7445.SABCS20-PD2-01","article-title":"Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE","volume":"81","author":"Harbeck","year":"2021","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000799","article-title":"Impact of primary antibody clone, format, and stainer platform on ki67 proliferation indices in breast carcinomas","volume":"27","author":"R\u00f8ge","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00745-6","article-title":"A new tool for technical standardization of the Ki67 immunohistochemical assay","volume":"34","author":"Aung","year":"2021","journal-title":"Modern Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172031","article-title":"A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method","volume":"12","author":"Jang","year":"2017","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0829","article-title":"Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B52","unstructured":"International Ki67 in Breast Cancer Working Group (IKWG)\n          \n          \n          2024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203174","article-title":"The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index","volume":"69","author":"Arima","year":"2016","journal-title":"J Clin Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01104-9","article-title":"Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study","volume":"35","author":"Acs","year":"2022","journal-title":"Mod Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2015.138","article-title":"Loss of antigenicity with tissue age in breast cancer","volume":"96","author":"Combs","year":"2016","journal-title":"Lab Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6215.DCIS22-A015","article-title":"A novel diagnostics approach to Ductal Carcinoma In Situ (DCIS) with potential impact on the therapeutic algorithms","volume":"15","author":"Schandiz","year":"2022","journal-title":"Cancer Prev Res"},{"key":"B58","unstructured":"Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av pasienter med brystkreft\n          \n          \n          2023"},{"key":"B59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trsl.2017.10.010","article-title":"Digital image analysis in breast pathology-from image processing techniques to artificial intelligence","volume":"194","author":"Robertson","year":"2018","journal-title":"Transl Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41379-018-0109-4","article-title":"An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer","volume":"32","author":"Rimm","year":"2019","journal-title":"Modern Pathol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13000-022-01225-4","article-title":"Visual and digital assessment of Ki-67 in breast cancer tissue - a comparison of methods","volume":"17","author":"Skjervold","year":"2022","journal-title":"Diagn Pathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1186\/s12885-019-6210-3","article-title":"External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41598-019-57094-3","article-title":"The prognostic and predictive potential of Ki-67 in triple-negative breast cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res Treat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1467664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:57:23Z","timestamp":1738303043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1467664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":65,"alternative-id":["10.3389\/fonc.2025.1467664"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1467664","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"article-number":"1467664"}}